Sep 16, 2013 | Coding, Billing, and Collections, Laboratory Management and Operations, Laboratory News, Laboratory Operations, Laboratory Pathology, Laboratory Sales and Marketing, Management & Operations, News From Dark Daily
Clinical laboratories and pathology groups serving Cigna beneficiaries can expect to see new requirements for genetic tests used to diagnose breast cancer, colon cancer and long QT syndrome
Effective this week, Cigna (NYSE: CI) in Bloomfield, Connecticut, is implementing a new program that requires genetic counseling and pre-authorization for certain genetic tests. This is an important development and clinical laboratory executives can expect to see other health insurers take similar steps.
Cigna wants to control costs and improve the appropriateness of ordering expensive genetic tests. It will start with tests for three conditions and may require counseling for other types of genetic tests if this program is successful. Industry observers expect other health insurers will follow Cigna’s example and also require genetic counseling for a compelling reason: all insurers recognize that more than 50% of all genetic tests may be ordered inappropriately, experts say.
(more…)
May 20, 2013 | Instruments & Equipment, Laboratory Instruments & Laboratory Equipment, Laboratory Management and Operations, Laboratory News, Laboratory Pathology
Steady progress is happening in consumer self-test kits as new diagnostic technology supports at-home kits that produce results with accuracy approaching 90%
Because screening for colon cancer represents a potentially huge number of medical laboratory tests each year, many biotech companies are racing to develop reliable test kits that patients can use at home. But to be successful, the test kit must be cheap, easy for a consumer to use, and produce clinically useful results.
Home Test Promises Same Accuracy as Clinical Laboratory Test
That’s the goal of Mode Diagnostics, Ltd., a Scottish company that is poised to sell a consumer device that can detect signs of colon cancer at home in three minutes at an accuracy rate of 98%. Mode’s new device is an example of how innovative diagnostic technology is driving the market for fast, accurate consumer self-test kits—and pushing these tests out of the central clinical laboratory and into the home. (more…)
May 13, 2013 | Instruments & Equipment, Laboratory Instruments & Laboratory Equipment, Laboratory Management and Operations, Laboratory News, Laboratory Operations, Laboratory Pathology
Pathologists and clinical laboratory managers may find new opportunities to increase testing volumes as patients’electronic health records yield clinically relevant data
Sophisticated use of electronic health records (EHRs), automated reminder systems, and telephone follow-up can double cancer-screening compliance by consumers. That could mean an increase in testing volumes for clinical laboratories serving clinics using this approach.
Researchers at the Group Health Research Institute (GHRI) used electronic health records to identify Group Health Cooperative (GHC) patients who weren’t screened regularly for cancer of the colon and rectum.
Because of how EHRs were used to step-up patient compliance for cancer screening, the study findings may be useful for pathologists and clinical laboratory managers. Over the years, many medical laboratories have furnished referring physicians a list of their patients who are due for screening tests, such as for cervical cancer. (more…)
Dec 27, 2011 | Instruments & Equipment, Laboratory Instruments & Laboratory Equipment, Laboratory Management and Operations, Laboratory News, Laboratory Operations, Laboratory Pathology, Management & Operations
Using monoclonal and polyclonal antibodies to detect only human blood in stool, this technology compares favorably when tested against other methodologies
New diagnostic technologies are literally tumbling out of research laboratories and biotech development companies at an increasing pace. The sheer volume of proprietary medical laboratory tests and new molecular diagnostic assays makes it a challenge for pathologists and clinical laboratory managers to identify which new lab tests have the greatest clinical value—and will also be adequately reimbursed by payers.
Each time a clinical laboratory wants to bring up a new medical laboratory test, it requires substantial effort. The laboratory will expend substantial financial, clinical, and operational resources to acquire the instrumentation, run the studies needed to validate the test, and begin the process of educating physicians about the value of the new test and how to use it in their medical practice. (more…)
